These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7075645)

  • 1. Correlation between pharmacokinetics and clinical effects of ergotamine in patients suffering from migraine.
    Ala-Hurula V
    Eur J Clin Pharmacol; 1982; 21(5):397-402. PubMed ID: 7075645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of ergotamine in migraine and cluster headache.
    Perrin VL
    Clin Pharmacokinet; 1985; 10(4):334-52. PubMed ID: 3899452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers.
    Ibraheem JJ; Paalzow L; Tfelt-Hansen P
    Eur J Clin Pharmacol; 1982; 23(3):235-40. PubMed ID: 7173294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ergotamine abuse: results of ergotamine discontinuation, with special reference to the plasma concentrations.
    Ala-Hurula V; Myllylä V; Hokkanen E
    Cephalalgia; 1982 Dec; 2(4):189-95. PubMed ID: 7159921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic availability of ergotamine tartrate after oral, rectal and intramuscular administration.
    Ala-Hurula V; Myllylä VV; Arvela P; Heikkilä J; Kärki N; Hokkanen E
    Eur J Clin Pharmacol; 1979 Feb; 15(1):51-5. PubMed ID: 421728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ergotamine in plasma and CSF after i.m. and rectal administration to humans.
    Hovdal H; Syversen GB; Rosenthaler J
    Cephalalgia; 1982 Sep; 2(3):145-50. PubMed ID: 7151147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic availability of ergotamine tartrate after three successive doses and during continuous medication.
    Ala-Hurula V; Myllylä VV; Arvela P; Kärki NT; Hokkanen E
    Eur J Clin Pharmacol; 1979 Nov; 16(5):355-60. PubMed ID: 520404
    [No Abstract]   [Full Text] [Related]  

  • 8. Ergotamine toxicity and serum concentrations of ergotamine in migraine patients.
    Graham AN; Johnson ES; Persaud NP; Turner P; Wilkinson M
    Hum Toxicol; 1984 Jun; 3(3):193-9. PubMed ID: 6430784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.
    Christie S; Göbel H; Mateos V; Allen C; Vrijens F; Shivaprakash M;
    Eur Neurol; 2003; 49(1):20-9. PubMed ID: 12464714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers.
    Ibraheem JJ; Paalzow L; Tfelt-Hansen P
    Br J Clin Pharmacol; 1983 Dec; 16(6):695-9. PubMed ID: 6419759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison.
    Diener HC; Jansen JP; Reches A; Pascual J; Pitei D; Steiner TJ;
    Eur Neurol; 2002; 47(2):99-107. PubMed ID: 11844898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic availability of ergotamine tartrate in continuous medication.
    Myllylä VV; Ala-Hurula V; Arvela P; Kärki N; Hokkanen E
    Ups J Med Sci Suppl; 1980; 31():20-2. PubMed ID: 6935854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine.
    Dahlöf C
    Cephalalgia; 1993 Jun; 13(3):166-71. PubMed ID: 8358774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pharmacodynamic effects and plasma levels of oral and rectal ergotamine.
    Bülow PM; Ibraheem JJ; Paalzow G; Tfelt-Hansen P
    Cephalalgia; 1986 Jun; 6(2):107-11. PubMed ID: 3091257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled clinical trial of ergotamine tartrate.
    Waters WE
    Br Med J; 1970 May; 2(5705):325-7. PubMed ID: 4913961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic availability of ergotamine tartrate in healthy subjects after single and repeated oral doses.
    Ala-Hurula V; Myllylä VV; Arvela P; Kärki NT; Hokkanen E
    Ups J Med Sci Suppl; 1980; 31():7-9. PubMed ID: 6935862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intramuscular ergotamine: plasma levels and dynamic activity.
    Tfelt-Hansen P; Paalzow L
    Clin Pharmacol Ther; 1985 Jan; 37(1):29-35. PubMed ID: 3917386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ergotamine: its use in the treatment of migraine and its complications.
    Saxena VK; De Deyn PP
    Acta Neurol (Napoli); 1992 Apr; 14(2):140-6. PubMed ID: 1329442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myocardial ischaemia in migraine sufferers taking ergotamine.
    Snell NJ; Russell-Smith C; Coysh HL
    Postgrad Med J; 1978 Jan; 54(627):37-9. PubMed ID: 625457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ergotamine Use and Overuse in Taiwan: A Retrospective Cohort Study.
    Chen CL; Yeh YC; Chen YY
    Headache; 2018 Mar; 58(3):416-423. PubMed ID: 29168165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.